Iteos Therapeutics, INC Schedule 13G passive stakes

Ridgeback Capital Investments L.P. and its affiliates have reported divesting their entire beneficial ownership in iTeos Therapeutics, Inc., now holding 0.0% of common stock.

Biotechnology Value Fund and its affiliates have fully divested their beneficial ownership in iTeos Therapeutics, Inc., holding 0% of common stock as of June 30, 2025.

Ridgeback Capital entities have reported a 5.1% beneficial ownership stake in iTeos Therapeutics, Inc., holding 1,942,959 common shares.

Ridgeback Capital Investments L.P., Ridgeback Capital Investments LLC, and Ridgeback Capital Management LLC have collectively reduced their beneficial ownership in iTeos Therapeutics, Inc. to 3.8% of outstanding common stock as of June 4, 2025.

A group of investment entities led by Biotechnology Value Fund, L.P. has disclosed an 8.1% passive beneficial ownership stake in iTeos Therapeutics, Inc. as of March 31, 2025.

Tang Capital Management, Kevin Tang, and affiliated entities have jointly reported beneficial ownership of 9.99% of ITeos Therapeutics, Inc.'s common stock.

EcoR1 Capital, LLC and its affiliates have reported an increased passive beneficial ownership of 14.9% in iTeos Therapeutics, Inc., holding 5,730,000 shares of common stock.

EcoR1 Capital, LLC and its control person Oleg Nodelman have reported a passive beneficial ownership of 6.9% in iTeos Therapeutics, Inc. common stock as of May 1, 2025.

BlackRock, Inc. has filed an Amendment No. 5 to Schedule 13G, disclosing a 5.7% beneficial ownership stake in ITEOS THERAPEUTICS INC common stock as of March 31, 2025.

BlackRock Portfolio Management LLC has filed a Schedule 13G, reporting a 6.1% beneficial ownership stake in ITEOS THERAPEUTICS INC as of March 31, 2025.

Tang Capital Management, along with its affiliated entities and Kevin Tang, has filed an amended Schedule 13G, revealing a passive 0.6% ownership stake in ITeos Therapeutics, Inc. as of December 31, 2024.